Dr. Jeymi Tambiah, MB ChB, FRCS, MS, FAPCR, FFPM

Chief Medical Officer

Jeymi Tambiah is a UK qualified physician scientist, who specialized as a cardiothoracic surgeon in London before entering the biopharmaceutical industry in 2008. Dr. Tambiah brings over 18 years of experience in clinical development, medical and regulatory strategy, and product commercialization across pharmaceutical and biotechnology organizations.

He has a strong track record of leading cross functional teams and advancing immunology programs, including novel therapeutics, through key clinical milestones. Previously, Dr. Tambiah held senior medical leadership roles at UCB, Biosplice Therapeutics, and Genascence, with responsibilities spanning clinical strategy, trial design and execution, regulatory interactions, and commercialization.

Dr. Tambiah earned his medical degrees from the Universities of St Andrews and Manchester (UK) and holds a research doctorate in vascular immunology from Imperial College London. He is a Fellow of the Academy of Physicians in Clinical Research (USA) and the Faculty of Pharmaceutical Medicine (UK).